This activity features presentations and downloadable slides highlighting the use of emerging novel therapies in recurrent GBM.
0.5 AMA PRA Category 1 Credit(s)™
Jun 14, 2019
Jun 14, 2020
Abstract #2006: Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors
Featured Expert: Alexander Drilon, MD
Abstract #2045: Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients
Featured Expert: Giuseppe Lombardi, MD
Alexander Drilon, MDMemorial Sloan Kettering Cancer Center
New York, New York, United States
Giuseppe Lombardi, MDIstituto Oncologico Veneto
This activity is designed for clinicians who are involved in the diagnosis, treatment, and management of patients with glioblastoma (GBM).
After successful completion of this educational activity, participants should be able to:
- Have increased knowledge of key data from the conference regarding emerging novel therapy for the management of GBM
- Have greater competence related to applying key data from the conference to clinical practice, as appropriate for patients with GBM
This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Jazz Pharmaceuticals; and Merck and Co, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 30 minutes
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Drilon has disclosed that he has received honoraria for participation on advisory boards from AstraZeneca, BeiGene, BergenBio, Blueprint Medicines, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, MORE Health, Pfizer, Takeda/Ariad/Millenium, TP Therapeutics, Tyra Biosciences, and Verastem. He has performed associated research paid to his institution for Exelixis, GlaxoSmithKlein, Pfizer, PharmaMar, Taiho, and Teva. He has received research funding from Foundation Medicine. He receives royalties from Wolters Kluwer. He has agreed disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Lombardi has disclosed that he has received consulting fees from AbbVie and Bayer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Dovey Ragoonath-Cameron, PhD (scientific content manager) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.